Neurogene, Inc. (NGNE)
28.31
-2.94
(-9.41%)
USD |
NASDAQ |
Sep 25, 16:00
28.32
+0.01
(+0.04%)
After-Hours: 19:59
Neurogene Net Income (Quarterly) : -34.49M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -34.49M |
| March 31, 2026 | -30.93M |
| December 31, 2025 | -24.74M |
| September 30, 2025 | -20.95M |
| June 30, 2025 | -22.02M |
| March 31, 2025 | -22.65M |
| December 31, 2024 | -19.51M |
| September 30, 2024 | -20.22M |
| June 30, 2024 | -18.49M |
| March 31, 2024 | -16.92M |
| December 31, 2023 | -15.50M |
| September 30, 2023 | -14.58M |
| June 30, 2023 | -2.085M |
| March 31, 2023 | -12.26M |
| December 31, 2022 | -13.44M |
| September 30, 2022 | -13.07M |
| June 30, 2022 | -15.69M |
| March 31, 2022 | -15.35M |
| December 31, 2021 | -15.17M |
| September 30, 2021 | -15.45M |
| June 30, 2021 | -15.13M |
| March 31, 2021 | -14.95M |
| December 31, 2020 | -12.64M |
| September 30, 2020 | -2.249M |
| June 30, 2020 | -9.746M |
| Date | Value |
|---|---|
| March 31, 2020 | -8.642M |
| December 31, 2019 | -8.101M |
| September 30, 2019 | -59.13M |
| June 30, 2019 | -0.001M |
| March 31, 2019 | -2.208M |
| December 31, 2018 | -4.887M |
| September 30, 2018 | -14.99M |
| June 30, 2018 | 2.918M |
| March 31, 2018 | -14.62M |
| December 31, 2017 | -16.27M |
| September 30, 2017 | -11.83M |
| June 30, 2017 | -13.77M |
| March 31, 2017 | -8.316M |
| December 31, 2016 | -11.24M |
| September 30, 2016 | -8.146M |
| June 30, 2016 | -10.90M |
| March 31, 2016 | -6.711M |
| December 31, 2015 | -5.663M |
| September 30, 2015 | -5.035M |
| June 30, 2015 | -4.75M |
| March 31, 2015 | -6.412M |
| December 31, 2014 | -8.090M |
| September 30, 2014 | -6.284M |
| June 30, 2014 | -5.425M |
| March 31, 2014 | -4.022M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 34.49M |
| EPS Diluted (Quarterly) | -1.529 |
| Enterprise Value | 231.11M |
| Earnings Yield | -19.44% |
| Normalized Earnings Yield | -19.44 |